The Role of Thoc1 in Normal Development and Cancer
Thoc1 在正常发育和癌症中的作用
基本信息
- 批准号:7332285
- 负责人:
- 金额:$ 35.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-01-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAllelesAnimalsBreastCell physiologyCellsClinicalCombined Modality TherapyComplexCouplesDNADNA DamageDefectDevelopmentDiagnosisDiagnosticDisabled PersonsDiseaseDisease ProgressionEngineeringEpigenetic ProcessEssential GenesExhibitsFaceGenesGeneticGrowthHPSE geneHealthHematologic NeoplasmsHeterogeneityHumanIn VitroLethal GenesLifeLongevityMalignant - descriptorMalignant NeoplasmsMammary glandMeasuresMinorMolecular TargetMutationNamesNormal CellNormal tissue morphologyNuclearNuclear ExportOrganismPTPNS1 genePhysiologicalPolymerasePopulationProcessProteinsRNARNA ProcessingRateRecurrenceResearchResistanceRoleSeedsSolid NeoplasmSpecificityStem cellsSynthetic GenesTestingTherapeutic IndexTransplantationYeastsbasecancer cellcancer stem cellcancer therapycarcinogenesiscell typehandicapping conditionin vivomalignant breast neoplasmmouse modelnoveloutcome forecastprognosticreconstitutionresearch studyresponsetheoriestumoryeast protein
项目摘要
The long-term objectives of this application are to understand the normal function of the Thod gene and to
assess its potential suitability as a molecular target for cancer therapy and prognosis. Thod encodes a
protein (pThocI) that has recently been identified as a component of the evolutionarily conserved TREX
complex. TREX is required for the efficient transcriptional elongation of a subset of genes, and it physically
couples elongation to the processes of RNA processing and nuclear export. The yeast orthologue of Thod
is not essential for viability, but loss of this gene causes reduced cellular lifespan, reduced growth rate, and
increased sensitivity to DNA damage. Similarly, human cancer cells depleted of pThod exhibit reduced
growth, viability, and resistance to genotoxic chemotherapeutics. In contrast, normal differentiated cells are
relatively unaffected by loss of pThod. The physiological requirements for Thod in normal development
and cancer have yet to be assessed in vivo in a multicellular organism. We hypothesize that cancer cells
are uniquely dependent on Thod expression for growth and viability, particularly in the presence of
DNA damage. The general experimental approach proposed for testing the hypothesis is to measure the
effects of pThod loss on normal development and malignant transformation using genetically engineered
Thod alleles and autochthonous mouse models of breast cancer. Four specific aims are proposed: 1) Test
whether pThod depletion inhibits malignant transformation in vitro. 2) Determine if pThod
depletion affects normal mammary gland development. 3) Ascertain whether pThod depletion
inhibits breast carcinogenesis in vivo. 4) Assess whether pThod levels influence the response of
breast cancer to genotoxic therapy. Cancer cells accumulate genetic and epigenetic alterations that
endow them with unwanted proliferative potential, but also burden them with unique vulnerabilities. Thus it is
possible to identify genes that are required for. the viability of cancer cells, but not normal cells. Such
synthetic lethal genetic interactions identify potential molecular targets for therapy that promise to yield
greater specificity for cancer cells. Successful completion of the proposed study will provide proof of principle
that Thod is such a molecular target. Since pThod is a component of the newly discovered TREX complex,
it functions with a novel mechanism of action. Therapies and diagnostics based on targeting pThod are
expected to yield novel clinical responses, opportunities for novel combination therapies, and prognostic
information potentially independent of currently used criteria. The proposed research is highly relevant to
human health because new molecularly targeted therapies with greater specificity for cancer cells are clearly
needed. The experiments proposed will determine whether pThod is a promising target for the development
of new therapies and prognostic tests.
该应用程序的长期目标是了解方法基因的正常功能和
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID W. GOODRICH其他文献
DAVID W. GOODRICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID W. GOODRICH', 18)}}的其他基金
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistance
YAP1和RB1合作调节肺癌谱系可塑性和治疗耐药性
- 批准号:
10829724 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
获得性治疗耐药网络协调和数据管理中心
- 批准号:
10516537 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
获得性治疗耐药网络协调和数据管理中心
- 批准号:
10682495 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10346091 - 财政年份:2019
- 资助金额:
$ 35.77万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10524127 - 财政年份:2019
- 资助金额:
$ 35.77万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10759015 - 财政年份:2019
- 资助金额:
$ 35.77万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10641672 - 财政年份:2019
- 资助金额:
$ 35.77万 - 项目类别:
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
NOTCH信号控制向雄激素非依赖性神经内分泌前列腺癌的转化
- 批准号:
10397535 - 财政年份:2019
- 资助金额:
$ 35.77万 - 项目类别:
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
(PQB5) Pten 和 Rb1 突变的时间是否影响前列腺癌表型
- 批准号:
8587206 - 财政年份:2013
- 资助金额:
$ 35.77万 - 项目类别:
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes
(PQB5) Pten 和 Rb1 突变的时间是否影响前列腺癌表型
- 批准号:
8708795 - 财政年份:2013
- 资助金额:
$ 35.77万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 35.77万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 35.77万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 35.77万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 35.77万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 35.77万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 35.77万 - 项目类别: